Wireline Network Holdings Llc
Total Consideration
$1.0K
Purchase-Price Allocation
Intangibles
$458.0M
Assets Acquired
$1.86B
Liabilities Assumed
$1.04B
Deferred Tax Liability
$474.9M
3 years of history · ending 2025-12-31 · SEC EDGAR
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
| Reconciliation Line | FY2017 | FY2018 | FY2025 |
|---|---|---|---|
| Federal Statutory Rate | 35.00% | 21.00% | 21.00% |
| State & Local Income Taxes | — | — | 7.10% |
| Foreign Rate Differential | — | — | -0.50% |
| Other Adjustments | — | — | — |
| Nondeductible Expenses | — | — | -1.00% |
| Effective Tax Rate | — | — | 25.60% |
Cash vs Accrual
| Item | FY2017 | FY2018 | FY2025 |
|---|---|---|---|
| Income Tax Expense (Accrual) | $25.2M | $12.7M | −$62.8M |
| Income Taxes Paid (Cash) | — | — | −$659.0K |
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
Total Consideration
$1.0K
Purchase-Price Allocation
Intangibles
$458.0M
Assets Acquired
$1.86B
Liabilities Assumed
$1.04B
Deferred Tax Liability
$474.9M
Phase 1: currency selection stored in the URL. Conversion ships in Phase 2 (see ADR-0003).